Free Trial

Pulmonx Q4 2023 Earnings Report

Pulmonx logo
$6.81 +0.08 (+1.25%)
As of 02:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmonx EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$0.38

Pulmonx Revenue Results

Actual Revenue
$19.30 million
Expected Revenue
$18.24 million
Beat/Miss
Beat by +$1.06 million
YoY Revenue Growth
+25.30%

Pulmonx Announcement Details

Quarter
Q4 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

Pulmonx Earnings Headlines

Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $13.36
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Pulmonx initiated with a Buy at D. Boral Capital
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
See More Pulmonx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email.

About Pulmonx

Pulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

View Pulmonx Profile

More Earnings Resources from MarketBeat